Efficacy of human simulated exposures of ceftaroline against phenotypically diverse Enterobacteriaceae isolates

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 5, 2012, Pages 2576-2580

  Housman, Seth T ^a   Keel, Rebecca A ^a   Crandon, Jared L ^a   Williams, Gregory ^b   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

^b Cerexa Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAROLINE FOSAMIL; CEFTAZIDIME; CEFTRIAXONE; LEVOFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG EFFICACY; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTION; ESCHERICHIA COLI; FEMALE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; SIMULATION;

ANIMALS; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; COLONY COUNT, MICROBIAL; DRUG ADMINISTRATION SCHEDULE; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; ESCHERICHIA COLI; FEMALE; HUMANS; IMMUNOCOMPETENCE; INJECTIONS, INTRAVENOUS; KLEBSIELLA; MICE; MICE, INBRED ICR; MICROBIAL SENSITIVITY TESTS; NEUTROPENIA; PHENOTYPE; THIGH;

EID: 84860120179     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06416-11     Document Type: Article

References (22)

1. Andes D, Craig WA. 1998. In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations. Antimicrob. Agents Chemother. 42:2375-2379. (Pubitemid 28420381)
2. Andes D, Craig WA. 2006. Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target. Antimicrob. Agents Chemother. 50:1376-1383.
3. Clinical and Laboratory Standards Institute. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 8th ed. M07-A8. Clinical and Laboratory Standards Institute, Wayne, PA.
4. Corey GR, et al. 2010. CANVAS 1: the first phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J. Antimicrob. Chemother. 65(Suppl 4):iv41-iv51.
5. Crandon JL, Bulik CC, Kuti JL, Nicolau DP. 2010. Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 54:1111-1116.
6. DeRyke CA, Lee SY, Kuti JL, Nicolau DP. 2006. Optimizing dosing strategies of antibacterials utilizing pharmacodynamic principles. Drugs 66:1-14. (Pubitemid 43144960)
7. Drusano GL. 2004. Antimicrobial pharmacodynamics: critical interactions of "bug and drug." Nat. Rev. Micriobiol. 2:289-300. (Pubitemid 39490099)
8. Feikin DR, et al. 2000. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am. J. Public Health 90:223-229. (Pubitemid 30062674)
9. File TM, Jr, et al. 2011. FOCUS 1: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J. Antimicrob. Chemother. 66(Suppl 3):iii19-iii32.
10. Forest Laboratories, Inc. 2010. Teflaro package insert. Forest Laboratories, Inc., St. Louis, MO.
11. Hoban DJ, Biedenbach DJ, Mutnick AH, Jones RN. 2003. Pathogen of occurrence and susceptibility patterns associated with pneumonia in hospitalized patients in North America: results of the SENTRY antimicrobial surveillance study (2000). Diagn. Microbiol. Infect. Dis. 45:279-285. (Pubitemid 36555680)
12. Jones RN, Farrel DJ, Mendes RE, Sader HS. 2011. Comparative ceftaroline activity tested against pathogens associated with communityacquired pneumonia: results from an international surveillance study. J. Antimicrob. Chemother. 66(Suppl 3):iii69-iii80.
13. Jones RN, Mendes RE, Sader HS. 2010. Ceftaroline activity against pathogens associated with complicated skin and skin structure infections: results from an international surveillance study. J. Antimicrob. Chemother. 65(Suppl 4):iv17-iv31.
14. Keel RA, Crandon JL, Nicolau DP. 2011. Efficacy of human simulated exposures of ceftaroline administered at 600 milligrams every 12 hours against phenotypically diverse Staphylococcus aureus isolates. Antimicrob. Agents Chemother. 55:4028-4032.
15. Lodise TP, Lomaestro BM, Drusano GL. 2006. Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on β-lactam antibiotics. Pharmacotherapy 26:1320-1332.
16. Low DE, et al. 2011. FOCUS 2: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J. Antimicrob. Chemother. 55(Suppl 3):iii33-iii44.
17. Marston BJ, et al. 1997. Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance study in Ohio. The Community-Based Pneumonia Incidence Study Group. Arch. Intern. Med. 157:1709-1718. (Pubitemid 27327407)
18. Moet GJ, Jones RN, Biedenbach DJ, Stilwell MG, Fritsche TR. 2007. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY antimicrobial surveillance program (1998-2004). Diagn. Microbiol. Infect. Dis. 57:7-13. (Pubitemid 44908825)
19. Niederman MS, et al. 2001. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am. J. Resp. Crit. Care Med. 163:1730-1754. (Pubitemid 32578779)
20. Turnidge JD. 1998. The pharmacodynamics of β-lactams. Clin. Infect. Dis. 27:10-22.
21. Wilcox MH, et al. 2010. CANVAS 2: the second phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J. Antimicrob. Chemother. 65(Suppl 4):iv53-iv65.
22. Wiskirchen DE, Crandon JL, Furtado GH, Williams G, Nicolau DP. 2011. In vivo efficacy of a human-simulated regimen of ceftaroline combined with NXL104 against extended-spectrum β-lactamase (ESBL)-producing and non-ESBL-producing Enterobacteriaceae. Antimicrob. Agents Chemother. 55:3220-3225.